X4 Pharmaceuticals (XFOR) Tops Q1 EPS by 24c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. REGN
2. CRWD
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. TFII
9. LYB
10. RXRX

Go back to X4 Pharmaceuticals (XFOR) Tops Q1 EPS by 24c

X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial Results

May 7, 2020 7:30 AM EDT

Data from Phase 2 open-label extension trial of mavorixafor in WHIM syndrome to be presented at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress in June 2020

Company continues to expect data from its Phase 1b Waldenströms macroglobulinemia trial in 2H 2020

Company expects a delay into 2022 to report top-line data from its pivotal Phase 3 clinical trial in WHIM syndrome, and a delay into 2021 to report initial data from its Phase 1b trial in Severe Congenital Neutropenia (SCN)... More